Free tool
FAERS Monitor: Xaciato
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215650 or its brand name (Xaciato, Clindamycin Phosphate). Reports on generic versions are filed under their own applications.
Reports
3,566
Serious
2,260
63% of reports
Hospitalization
1,051
Death reported
264
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective375
- rash257
- drug hypersensitivity230
- off label use227
- diarrhoea190
- nausea186
- fatigue169
- pruritus168
- pain161
- condition aggravated135
- dyspnoea114
- headache113
- product use in unapproved indication109
- pyrexia108
- erythema101
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 18 |
| 2005 | 48 |
| 2006 | 56 |
| 2007 | 14 |
| 2008 | 20 |
| 2009 | 43 |
| 2010 | 82 |
| 2011 | 65 |
| 2012 | 95 |
| 2013 | 101 |
| 2014 | 102 |
| 2015 | 124 |
| 2016 | 242 |
| 2017 | 182 |
| 2018 | 237 |
| 2019 | 276 |
| 2020 | 210 |
| 2021 | 194 |
| 2022 | 288 |
| 2023 | 305 |
| 2024 | 286 |
| 2025 | 309 |
| 2026 | 268 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,593 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 230 | 7.0 | 6.2 | 1,190 |
| rashSignal | 257 | 3.5 | 3.1 | 461 |
| erythemaSignal | 101 | 2.9 | 2.4 | 125 |
| condition aggravatedSignal | 135 | 2.6 | 2.2 | 135 |
| product use in unapproved indicationSignal | 109 | 2.6 | 2.2 | 106 |
| pruritusSignal | 168 | 2.6 | 2.2 | 164 |
| pyrexia | 108 | 1.8 | 1.5 | 41 |
| diarrhoea | 190 | 1.7 | 1.5 | 60 |
| drug ineffective | 375 | 1.7 | 1.5 | 109 |
| pain | 161 | 1.5 | 1.3 | 31 |
| off label use | 227 | 1.5 | 1.3 | 43 |
| nausea | 186 | 1.4 | 1.2 | 20 |
| fatigue | 169 | 1.3 | 1.1 | 10 |
| dyspnoea | 114 | 1.2 | 1.0 | 3 |
| headache | 113 | 1.1 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.